LYEL Stock Overview
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lyell Immunopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.33 |
| 52 Week High | US$3.97 |
| 52 Week Low | US$1.32 |
| Beta | -0.56 |
| 1 Month Change | 17.09% |
| 3 Month Change | 22.63% |
| 1 Year Change | 4.02% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.20% |
Recent News & Updates
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Apr 16Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Feb 23
Recent updates
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Apr 16Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Feb 23Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Nov 09Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher
Aug 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Aug 11Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
Dec 15Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845
Oct 06Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Sep 12News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts
Aug 08Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Apr 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Sep 17Shareholder Returns
| LYEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.4% | -4.2% | -3.7% |
| 1Y | 4.0% | -2.0% | 20.5% |
Return vs Industry: LYEL exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: LYEL underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| LYEL volatility | |
|---|---|
| LYEL Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LYEL's share price has been volatile over the past 3 months.
Volatility Over Time: LYEL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 224 | Lynn Seely | lyell.com |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications.
Lyell Immunopharma, Inc. Fundamentals Summary
| LYEL fundamental statistics | |
|---|---|
| Market cap | US$592.04m |
| Earnings (TTM) | -US$234.63m |
| Revenue (TTM) | US$130.00k |
4,554x
P/S Ratio-2.5x
P/E RatioIs LYEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYEL income statement (TTM) | |
|---|---|
| Revenue | US$130.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$130.00k |
| Other Expenses | US$234.76m |
| Earnings | -US$234.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 100.00% |
| Net Profit Margin | -180,486.15% |
| Debt/Equity Ratio | 0% |
How did LYEL perform over the long term?
See historical performance and comparison